Labopharm (Seller)Paladin (Buyer)
Paladin acquiring Labopharm for C$0.29 per share in cash, or C$20.4 million ($20.7 million) based on 71.6 million shares outstanding
Labopharm (Licensor)Angelini (Investor)
Labopharm Inc. and Gruppo Angelini will form a JV, Angelini Labopharm, to market Oleptro trazodone extended-release tablets to treat major depressive disorder (MDD) in the U.S.
Set Email Alert